visualizations
Mori, Shahram, MD, PhD
Overview
overview
- Shahram Mori, MD, PhD is a highly experienced physician with board-certification in oncology and hematology. After earning a PhD in molecular biology from New Mexico State University, Dr. Mori went on to receive fellowship training in oncology/hematology from Arizona Cancer Center, University of Arizona in Tucson and bone marrow transplantation from City of Hope National Medical Center in Duarte, California. He specializes in treating a wide array of complex blood disorders using blood and bone-marrow transplantation and cellular therapy.
Affiliation
Member of
-
Research Department
Publications
Most Recent Publications
-
2022Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation. ANNALS OF HEMATOLOGY.Full Text via DOI: 10.1007/s00277-022-05042-z PMID: 36462061
-
2022Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience. INTERNATIONAL JOURNAL OF HEMATOLOGY.Full Text via DOI: 10.1007/s12185-022-03493-8 PMID: 36378406
-
2020Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. HAEMATOLOGICA. 105:1329-1338.Full Text via DOI: 10.3324/haematol.2019.220756 PMID: 31558669
-
2020Role of Post-Allogeneic Hematopoietic Stem Cell Transplantation Low-Dose Azacitidine for Prevention of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S126-S127.
-
2020Ruxolitinib Is a Safe and Effective Therapeutic Option for Management of Chronic Gvhd - a Single Center Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S193-S194.
-
2019Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment. CURRENT TREATMENT OPTIONS IN ONCOLOGY.Full Text via DOI: 10.1007/s11864-019-0684-8 PMID: 31776787
-
2019Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 25:1320-1324.Full Text via DOI: 10.1016/j.bbmt.2019.01.027 PMID: 30710685
-
2019Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome. BONE MARROW TRANSPLANTATION. 924-927.Full Text via DOI: 10.1038/s41409-018-0407-y PMID: 30563982
-
2019Higher Risks of Toxicity and Incomplete Recovery in 13-to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 25:955-964.Full Text via DOI: 10.1016/j.bbmt.2018.12.765 PMID: 30605731
-
2019Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma. CUREUS. 11.Full Text via DOI: 10.7759/cureus.4401 PMID: 31245191
-
2019Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 25:699-711.Full Text via DOI: 10.1016/j.bbmt.2018.11.004 PMID: 30423480
-
2019Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. HAEMATOLOGICA. 104:844-854.Full Text via DOI: 10.3324/haematol.2018.200121 PMID: 30381298
-
2019The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. BLOOD ADVANCES. 3:670-680.Full Text via DOI: 10.1182/bloodadvances.2018027003 PMID: 30808685
-
2019Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19:E93-E97.Full Text via DOI: 10.1016/j.clml.2018.11.007 PMID: 30559058
-
2018Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia. BLOOD.Full Text via DOI: 10.1182/blood-2018-99-120285
-
2018Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. BRITISH JOURNAL OF HAEMATOLOGY. 916-920.Full Text via DOI: 10.1111/bjh.14879 PMID: 28771676
-
2018Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation: Case report and review of the literature. TRANSPLANT INFECTIOUS DISEASE.Full Text via DOI: 10.1111/tid.12879 PMID: 29512846
-
2018Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma with P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S253-S254.
-
2018Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S343-S344.
-
2018Post-Transplant Low-Dose Azacitidine Can Improve Overall Survival in AML/MDS Patients and is Associated with Decrease Risks of Severe Acute and Chronic Gvhd. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S327-S327.
-
2018Residual Leukemia in the Bone Marrow and/or Peripheral Blood on Day 7 of Blinatumomab Therapy Predicts Response in B-Cell Acute Lymphoblastic Leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S237-S237.
-
2018Use of Nitazoxanide, an Anti-Parasitic Drug, for Management of Norovirus Ileo-Colitis in an Allogeneic Stem Cell Transplant Patient. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S394-S395.
-
2017Nivolumab is Effective in Relapsed Refractory Hodgkins Lymphoma Patient Following Mismatched Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S263-S264.
-
2017Sternal Soft Tissue Mass as Initial Presentation in a Case of Acute Promyelocytic Leukemia (APL). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S208-S208.
-
2017Transverse Myelitis As a Manifestation of Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S310-S310.
-
2016Low Dose Steroids Can Improve High Grade Febrile Episodes Associated with Blinatumomab Therapy and Limit Treatment Interruptions without Affecting Anti Leukemic Effects. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S195-S195.
-
2016Steroid Refractory Acute Liver GVHD in a Hodgkin's Patient after Allogeneic Stem Transplant Cell Transplantation Following Treatment with Anti PD-1 Antibody, Nivolumab, for Relapsed Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S392-S393.
-
2016Thymoglobulin after Matched Unrelated Hematopoietic Stem Cell Transplantation (HCT) in AML/MDS Results in Improved Outcomes Comparable to Matched Related HCT. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S329-S330.
Background
Full Name
- Shahram Mori, MD
Education
- St. George's University School of Medicine
Residency
- University of Texas Medical School at Houston
Fellowship
- City of Hope University of Arizona College of Medicine
Board Certification
- Medical Oncology: American board of Internal Medicine
Contact
primary email
- Research.Institute@AdventHealth.com